Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Diabetologia|November 15, 2011
Pathophysiology of postprandial hyperglycaemia in women with type 1 diabetes during pregnancyH R Murphy, D Elleri, J M Allen, et al.
Transplantation and Cellular Therapy|December 9, 2025
Fludarabine Pharmacokinetic Model-Based Dosing Minimizes the Risk of Graft Rejection in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell TransplantationChristopher C Dvorak, Ella Waters, William C Temple, et al.
Transplantation and Cellular Therapy|February 12, 2025
Younger children with nonmalignant disease have increased incidence of mixed myeloid chimerism after allogeneic hematopoietic cell transplantation with busulfan-based conditioningChristopher C Dvorak, William C Temple, Gabriel Salinas Cisneros, et al.
Journal for Immunotherapy of Cancer|November 25, 2023
Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignanciesWilliam C Temple, Matthew A Nix, Akul Naik, et al.
Transplantation and Cellular Therapy|April 4, 2025
High Melphalan Exposure Increases the Risk of Graft-Versus-Host Disease in Pediatric Patients Undergoing Alpha-Beta T-Cell Depleted Haploidentical TransplantationChristopher C Dvorak, Soohee Cho, Gabriel Salinas Cisneros, et al.
Nature Communications|April 23, 2025
Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemiaJuwita Werner, Alex G Lee, Chujing Zhang, et al.
Journal for Immunotherapy of Cancer|December 30, 2025
Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignanciesAdila Izgutdina, Tasfia Rashid, William C Temple, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2025
Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell MalignanciesAdila Izgutdina, Tasfia Rashid, William C Temple, et al.
Nature Cancer|October 31, 2023
Structural surfaceomics reveals an AML-specific conformation of integrin β<sub>2</sub> as a CAR T cellular therapy targetKamal Mandal, Gianina Wicaksono, Clinton Yu, et al.
Pageof 9